Intellia Therapeutics, Inc.
NTLA
$8.84
$0.202.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 57.88M | 43.09M | 45.97M | 52.60M | 36.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.88M | 43.09M | 45.97M | 52.60M | 36.28M |
| Cost of Revenue | 466.31M | 458.42M | 448.73M | 449.80M | 435.07M |
| Gross Profit | -408.43M | -415.33M | -402.76M | -397.20M | -398.79M |
| SG&A Expenses | 125.83M | 122.38M | 121.28M | 120.14M | 116.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 592.14M | 580.79M | 570.01M | 569.94M | 551.57M |
| Operating Income | -534.26M | -537.71M | -524.05M | -517.34M | -515.29M |
| Income Before Tax | -519.02M | -522.28M | -508.80M | -485.50M | -481.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -519.02 | -522.28 | -508.80 | -485.50 | -481.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -519.02M | -522.28M | -508.80M | -485.50M | -481.19M |
| EBIT | -534.26M | -537.71M | -524.05M | -517.34M | -515.29M |
| EBITDA | -523.98M | -527.52M | -514.18M | -507.90M | -506.32M |
| EPS Basic | -5.25 | -5.45 | -5.48 | -5.37 | -5.42 |
| Normalized Basic EPS | -3.07 | -3.21 | -3.25 | -3.31 | -3.39 |
| EPS Diluted | -5.25 | -5.45 | -5.48 | -5.37 | -5.42 |
| Normalized Diluted EPS | -3.07 | -3.21 | -3.25 | -3.31 | -3.39 |
| Average Basic Shares Outstanding | 395.33M | 383.94M | 371.58M | 362.79M | 355.06M |
| Average Diluted Shares Outstanding | 395.33M | 383.94M | 371.58M | 362.79M | 355.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |